|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM349238596 |
| 003 |
DE-627 |
| 005 |
20231226042139.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.109186
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1164.xml
|
| 035 |
|
|
|a (DE-627)NLM349238596
|
| 035 |
|
|
|a (NLM)36410686
|
| 035 |
|
|
|a (PII)S1521-6616(22)00267-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Fragoulis, George E
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treat to target in Behcet's disease
|b Should we follow the paradigm of other systemic rheumatic diseases?
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.01.2023
|
| 500 |
|
|
|a Date Revised 12.02.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a During the last decades the efficacy of biologic agents, mainly of anti-TNFs, in controlling the activity of serious manifestations of Behcet's Disease (BD) has been established. On the other hand, the clinical heterogeneity of BD has precluded the validation of a widely-accepted composite index for disease assessment and for target disease-state definitions, such as low disease activity and remission, and the testing of their implementation in clinical practice. Therefore, in contrast to other systemic rheumatic diseases, a treat-to-target strategy has not yet been developed in BD. There are several challenges towards this approach, including standardization of outcome measures for assessing the disease activity in each-affected organ and construction of a composite disease activity index. The challenges for the development of a treat-to-target strategy and possible solutions are discussed in this position paper, which stemmed from a round table discussion that took place in the 19th International Conference on BD
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Behcet's disease
|
| 650 |
|
4 |
|a Disease activity
|
| 650 |
|
4 |
|a Treat-to-target
|
| 650 |
|
7 |
|a Biological Factors
|2 NLM
|
| 700 |
1 |
|
|a Bertsias, George
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bodaghi, Bahram
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gul, Ahmet
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a van Laar, Jan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mumcu, Gonca
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Saadoun, David
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tugal-Tutkun, Ilknur
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hatemi, Gulen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sfikakis, Petros P
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 246(2023) vom: 01. Jan., Seite 109186
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:246
|g year:2023
|g day:01
|g month:01
|g pages:109186
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.109186
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 246
|j 2023
|b 01
|c 01
|h 109186
|